{"nctId":"NCT02991118","briefTitle":"Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk","startDateStruct":{"date":"2016-11-18","type":"ACTUAL"},"conditions":["Hypercholesterolemia","Atherosclerotic Cardiovascular Disease"],"count":779,"armGroups":[{"label":"bempedoic acid","type":"EXPERIMENTAL","interventionNames":["Drug: bempedoic acid"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"bempedoic acid","otherNames":["ETC-1002"]},{"name":"placebo","otherNames":["placebo control"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Fasting LDL-C ≥100 mg/dL\n* High cardiovascular risk (diagnosis of HeFH and/or ASCVD)\n* Be on maximally tolerated lipid-modifying therapy (LMT), including maximally tolerated statin either alone or in combination with other LMTs\n\nExclusion Criteria:\n\n* Total fasting triglyceride ≥500 mg/dL\n* Renal dysfunction or nephrotic syndrome or history of nephritis\n* Body Mass Index (BMI) ≥50kg/m2\n* Significant cardiovascular disease or cardiovascular event in the past 3 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)","description":"Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\\[post-baseline value minus baseline value\\] divided by \\[baseline value\\]) multiplied by 100. Percent change from Baseline in LDL-C was analyzed using an analysis of covariance (ANCOVA) model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (atherosclerotic cardiovascular diseases \\[ASCVD\\] and heterozygous familial hypercholesterolemia \\[HeFH\\]) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing LDL-C data at Week 12 are imputed using multiple imputation method taking into account adherence to treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.35","spread":"1.446"},{"groupId":"OG001","value":"-15.07","spread":"1.073"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 24 in LDL-C","description":"Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\\[post-baseline value minus baseline value\\] divided by \\[baseline value\\]) multiplied by 100. Percent change from Baseline in LDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing LDL-C data at Week 24 were imputed using multiple imputation method taking into account adherence to treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.66","spread":"1.910"},{"groupId":"OG001","value":"-12.10","spread":"1.479"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)","description":"Baseline is defined as the mean of the non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\\[post-baseline value minus baseline value\\] divided by \\[baseline value\\]) multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing non-HDL-C data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.28","spread":"1.351"},{"groupId":"OG001","value":"-10.75","spread":"0.952"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 12 in Total Cholesterol (TC)","description":"Baseline is defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\\[post-baseline value minus baseline value\\] divided by \\[baseline value\\]) multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing TC data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.26","spread":"1.010"},{"groupId":"OG001","value":"-9.94","spread":"0.688"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 12 in Apolipoprotein b (Apo B)","description":"Baseline for apo B was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\\[post-baseline value minus baseline value\\] divided by \\[baseline value\\]) multiplied by 100. Percent change from Baseline in apo B was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate. In the ANCOVA model, missing apo B data at Week 12 were imputed using multiple imputation method taking into account adherence to treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.73","spread":"1.340"},{"groupId":"OG001","value":"-9.29","spread":"0.851"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)","description":"Baseline for hsCRP was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\\[post-baseline value minus baseline value\\] divided by \\[baseline value\\]) multiplied by 100.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.366","spread":null},{"groupId":"OG001","value":"-18.699","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 12 in LDL-C","description":"Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Change from Baseline is calculated as the post-baseline value minus the baseline value. Analysis was conducted using descriptive statistics by treatment group using observed data.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"30.62"},{"groupId":"OG001","value":"-21.2","spread":"30.82"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 24 in LDL-C","description":"Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Change from Baseline is calculated as the post-baseline value minus the baseline value. Analysis was conducted using descriptive statistics by treatment group using observed data.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"37.51"},{"groupId":"OG001","value":"-18.7","spread":"35.76"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline to Week 12 in Triglycerides (TGs)","description":"Baseline is defined as the mean of the TG values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\\[post-baseline value minus baseline value\\] divided by \\[baseline value\\]) multiplied by 100. Percent change from Baseline in TG was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.12","spread":"2.294"},{"groupId":"OG001","value":"11.01","spread":"2.312"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline to Week 12 in HDL-C","description":"Baseline is defined as the mean of the HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\\[post-baseline value minus baseline value\\] divided by \\[baseline value\\]) multiplied by 100. Percent change from Baseline in HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"0.864"},{"groupId":"OG001","value":"-6.38","spread":"0.741"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline to Week 52 in LDL-C","description":"Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\\[post-baseline value minus baseline value\\] divided by \\[baseline value\\]) multiplied by 100. Percent change from Baseline in LDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.97","spread":"1.830"},{"groupId":"OG001","value":"-13.24","spread":"1.412"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline to Week 24 in Non-HDL-C","description":"Baseline was defined as the mean of the non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\\[post-baseline value minus baseline value\\] divided by \\[baseline value\\]) multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.44","spread":"1.611"},{"groupId":"OG001","value":"-10.19","spread":"1.200"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline to Week 52 in Non-HDL-C","description":"Baseline was defined as the mean of the non-HDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\\[post-baseline value minus baseline value\\] divided by \\[baseline value\\]) multiplied by 100. Percent change from Baseline in non-HDL-C was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.42","spread":"1.605"},{"groupId":"OG001","value":"-10.34","spread":"1.150"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline to Week 24 in TC","description":"Baseline was defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\\[post-baseline value minus baseline value\\] divided by \\[baseline value\\]) multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.52","spread":"1.216"},{"groupId":"OG001","value":"-9.25","spread":"0.857"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline to Week 52 in TC","description":"Baseline was defined as the mean of the TC values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\\[post-baseline value minus baseline value\\] divided by \\[baseline value\\]) multiplied by 100. Percent change from Baseline in TC was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.89","spread":"1.199"},{"groupId":"OG001","value":"-10.25","spread":"0.828"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline to Week 24 in Apo B","description":"Baseline for apo B was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\\[post-baseline value minus baseline value\\] divided by \\[baseline value\\]) multiplied by 100. Percent change from Baseline in apo B was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.39","spread":"2.090"},{"groupId":"OG001","value":"-8.61","spread":"1.267"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline to Week 52 in Apo B","description":"Baseline for apo B was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\\[post-baseline value minus baseline value\\] divided by \\[baseline value\\]) multiplied by 100. Percent change from Baseline in apo B was analyzed using an ANCOVA model with percent change from Baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and Baseline as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.01","spread":"1.502"},{"groupId":"OG001","value":"-6.56","spread":"0.983"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline to Week 24 in hsCRP","description":"Baseline for hsCRP was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\\[post-baseline value minus baseline value\\] divided by \\[baseline value\\]) multiplied by 100.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.563","spread":null},{"groupId":"OG001","value":"-24.107","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline to Week 52 in hsCRP","description":"Baseline for hsCRP was defined as the last non-missing value on or prior to Day 1. Percent change from Baseline is calculated as (\\[post-baseline value minus baseline value\\] divided by \\[baseline value\\]) multiplied by 100.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.250","spread":null},{"groupId":"OG001","value":"-16.727","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline to Week 52 in LDL-C","description":"Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Change from Baseline is calculated as the post-baseline value minus the baseline value. Analysis was conducted using descriptive statistics by treatment group using observed data. Change from Baseline in LDL-C was analyzed using an ANCOVA model with change from baseline as the dependent variable, treatment, cardiovascular risk (ASCVD and HeFH) crossed with Baseline statin intensity (low/moderate and high) as fixed effects and baseline as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.71","spread":"2.216"},{"groupId":"OG001","value":"-19.78","spread":"1.433"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":48,"n":257},"commonTop":["Nasopharyngitis","Urinary tract infection","Upper respiratory tract infection","Hyperuricaemia","Arthralgia"]}}}